文献速递病毒性肝炎艾滋病与性传播感染

持续病毒学应答时肝脏硬度预测HIV/HCV合并晚期纤维化患者的临床结局

Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
PubMed 文献 · Clin Infect Dis · 2020-01-01

本研究纳入640例接受直接抗病毒药物(DAA)治疗并取得持续病毒学应答(SVR)的HIV/HCV合并晚期纤维化患者,分析SVR时肝脏硬度(LS)对肝脏并发症的预测能力。中位随访31.6个月,19例(3%)达到主要终点;多因素分析显示SVR时LS每增加1 kPa与结局风险独立相关(SHR 1.05,95%CI 1.02-1.08),且374例LS<14 kPa者均未发生肝脏并发症或需肝移植。结论提示SVR时LS测量有助于筛选可退出监测的患者。

要点

  • SVR时LS每增加1 kPa,肝脏并发症风险独立增加5%(SHR 1.05,95%CI 1.02-1.08)。
  • SVR时LS<14 kPa的374例患者均未发生肝脏并发症或需肝移植。
  • SVR时CD4<200/μL与肝脏并发症风险独立相关(SHR 4.42,95%CI 1.49-13.15)。

核心结论

  • DAA治疗后SVR时的肝脏硬度可预测HIV/HCV合并晚期纤维化患者的临床结局。
  • SVR时LS测量可能有助于筛选可退出监测程序的患者。

研究设计与样本

  • 纳入640例HIV/HCV合并晚期纤维化患者,均接受含DAA方案并取得SVR,且治疗前LS≥9.5 kPa、SVR时有LS测量值。
  • 主要终点为SVR后发生肝脏并发症(肝失代偿或肝细胞癌)或需肝移植。
  • 中位随访31.6个月(Q1-Q3 22.7-36.6)。

主要发现

  • 随访期间19例(3%)达到主要终点。
  • 多因素分析中与结局相关的变量包括:既往肝失代偿(SHR 3.42,95%CI 1.28-9.12)、治疗前CPT B或C级(SHR 62.5,95%CI 3.08-1246.42)、MELD评分(SHR 1.37,95%CI 1.03-1.82)、SVR时CPT B或C级(SHR 10.71,95%CI 1.32-87.01)、SVR时CD4<200/μL(SHR 4.42,95%CI 1.49-13.15)、SVR时FIB-4指数(SHR 1.39,95%CI 1.13-1.70)、SVR时LS每增加1 kPa(SHR 1.05,95%CI 1.02-1.08)。
  • SVR时LS<14 kPa的374例患者均未发生肝脏并发症或需肝移植。

关键数值与推荐

  • 纳入标准:DAA方案取得SVR;治疗前LS≥9.5 kPa;SVR时有LS测量值。
  • 主要终点:肝失代偿、肝细胞癌或需肝移植。

临床怎么用

  • 对于HIV/HCV合并晚期纤维化且取得SVR的患者,可通过SVR时LS测量评估肝脏并发症风险。
  • SVR时LS<14 kPa可能提示肝脏并发症风险极低,或可考虑退出监测程序。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some people living with hepatitis C virus (HCV) with sustained virological response (SVR) develop hepatic complications. Liver stiffness (LS) predicts clinical outcome in people living with human immunodeficiency virus (HIV) with active HCV coinfection, but information after SVR is lacking. We aimed to analyze the predictive ability of LS at SVR for liver complications in people living with HIV/HCV with advanced fibrosis treated with direct-acting antivirals (DAA). METHODS: In sum, 640 people living with HIV/HCV fulfilling the following criteria were included: (i) Achieved SVR with DAA-including regimen; (ii) LS ≥ 9.5 kPa before therapy; and (iii) LS measurement available at SVR. The primary endpoint was the occurrence of a liver complication-hepatic decompensation or hepatocellular carcinoma (HCC)-or requiring liver transplant after SVR. RESULTS: During a median (Q1-Q3) follow-up of 31.6 (22.7-36.6) months, 19 (3%) patients reached the primary endpoint. In the multivariate analysis, variables (subhazard ratio [SHR] [95% confidence interval]) associated with developing clinical outcomes were: prior hepatic decompensations (3.42 [1.28-9.12]), pretreatment CPT class B or C (62.5 [3.08-1246.42]) and MELD scores (1.37 [1.03-1.82]), CPT class B or C at SVR (10.71 [1.32-87.01]), CD4 cell counts <200/µL at SVR time-point (4.42 [1.49-13.15]), FIB-4 index at SVR (1.39 [1.13-1.70]), and LS at SVR (1.05 [1.02-1.08] for 1 kPa increase). None of the 374 patients with LS <14kPa at SVR time-point developed a liver complication or required hepatic transplant. CONCLUSIONS: LS at the time of SVR after DAA therapy predicts the clinical outcome of people living with HIV/HCV with advanced fibrosis. These results suggest that LS measurement may be helpful to select candidates to be withdrawn from surveillance programs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Corma-Gómez A, Macías J, Téllez F, et al. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Clin Infect Dis. 2020. PMID: 31754695. doi:10.1093/cid/ciz1140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。